Biologic response modifiers presently approved in the USA for use in various rheumatic inflammatory diseases include three TNF inhibitors (etanercept, infliximab and adalimumab), a B-cell-directed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results